Taiho Oncology and Cullinan Therapeutics said on Friday that data from their Phase 3 REZILIENT3 trial will be presented at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer.
The trial evaluated Zipalertinib, an investigational orally available EGFR-targeting small molecule, in combination with chemotherapy versus chemotherapy alone in 285 adults with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. The study met its primary endpoint of progression-free survival in the first-line treatment setting.
Results will be delivered during the Presidential Symposium 2 on September 14, 2026, at 8 a.m. KST, by Dr. Daniel Tan Shao Weng of Duke Health, Singapore. The conference is scheduled for September 12–15, 2026.
Zipalertinib remains investigational and has not been approved by any health authority. NSCLC accounts for approximately 85% of all lung cancer cases globally, with up to 4% of these cases involving EGFR exon 20 insertion mutations. In the United States, about 16% of NSCLC patients have EGFR mutations, of which insertions at exon 20 represent up to 12%.
Taiho Oncology is headquartered in Princeton, N.J., while Cullinan Therapeutics operates from Cambridge, Mass. Cullinan Oncology LLC and Taiho Pharmaceutical Co., Ltd. are also involved in the trial, which is conducted across multiple global sites including Seoul and Singapore.
